Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Enterprise Value to EBITDA (EV/EBITDA)

Microsoft Excel

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

Abiomed Inc., EBITDA calculation

US$ in thousands

Microsoft Excel
12 months ended: Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Net income 136,505 225,525 203,009 259,016 112,170 52,116
Add: Income tax expense 54,055 62,695 53,816 4,344 48,267 39,227
Earnings before tax (EBT) 190,560 288,220 256,825 263,360 160,437 91,343
Add: Interest expense 302 354
Earnings before interest and tax (EBIT) 190,560 288,220 256,825 263,360 160,739 91,697
Add: Depreciation and amortization 28,089 24,097 20,430 14,121 11,005 6,202
Earnings before interest, tax, depreciation and amortization (EBITDA) 218,649 312,317 277,255 277,481 171,744 97,899

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

Item Description The company
EBITDA To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. Abiomed Inc. EBITDA increased from 2020 to 2021 but then decreased significantly from 2021 to 2022.

Enterprise Value to EBITDA Ratio, Current

Abiomed Inc., current EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in thousands)
Enterprise value (EV) 16,088,812
Earnings before interest, tax, depreciation and amortization (EBITDA) 218,649
Valuation Ratio
EV/EBITDA 73.58
Benchmarks
EV/EBITDA, Competitors1
Abbott Laboratories 18.34
Cigna Group 12.61
CVS Health Corp. 7.58
Elevance Health Inc. 10.73
Humana Inc. 6.34
Intuitive Surgical Inc. 52.81
Medtronic PLC 14.21
Shockwave Medical Inc. 62.80
UnitedHealth Group Inc. 13.42
EV/EBITDA, Sector
Health Care Equipment & Services 14.06
EV/EBITDA, Industry
Health Care 14.70

Based on: 10-K (reporting date: 2022-03-31).

1 Click competitor name to see calculations.

If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.


Enterprise Value to EBITDA Ratio, Historical

Abiomed Inc., historical EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Enterprise value (EV)1 9,983,091 12,099,179 8,382,834 11,359,861 17,182,479 5,740,561
Earnings before interest, tax, depreciation and amortization (EBITDA)2 218,649 312,317 277,255 277,481 171,744 97,899
Valuation Ratio
EV/EBITDA3 45.66 38.74 30.24 40.94 100.05 58.64
Benchmarks
EV/EBITDA, Competitors4
Abbott Laboratories 15.85 17.42 25.99 21.70
Cigna Group 8.88 9.06 6.31 8.42
CVS Health Corp. 12.42 10.41 8.56 9.43
Elevance Health Inc. 10.26 10.05 7.57 9.05
Humana Inc. 11.59 11.22 6.91 9.30
Intuitive Surgical Inc. 41.52 44.54 59.12 37.53
Medtronic PLC 14.99 24.41 17.92 16.01 13.94
Shockwave Medical Inc. 52.02
UnitedHealth Group Inc. 15.11 17.39 13.39 13.82
EV/EBITDA, Sector
Health Care Equipment & Services 13.91 15.27 12.79 12.97
EV/EBITDA, Industry
Health Care 13.80 13.98 16.48 14.28

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 See details »

2 See details »

3 2022 Calculation
EV/EBITDA = EV ÷ EBITDA
= 9,983,091 ÷ 218,649 = 45.66

4 Click competitor name to see calculations.

Valuation ratio Description The company
EV/EBITDA Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. Abiomed Inc. EV/EBITDA ratio increased from 2020 to 2021 and from 2021 to 2022.